One of the challenges for the adolescent and young adult (AYA) cancer population is the transition of adolescent cancer survivors treated at pediatric institutions to adult-based providers in their young adult years. Unfortunately, most AYA survivors are not enrolled and followed in survivorship programs and are oftentimes treated by primary care physicians who are unfamiliar with AYA cancers and the long-term effects and issues associated with them.
Source: Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer, Report of the Adolescent and Young Adult Oncology Progress Review Group. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute, LIVESTRONG™ Young Adult Alliance; NIH Pub. 06-6067; 2006.
Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols.
Pediatr Blood Cancer. 2006 Nov;47(6):748-56
Authors: Ramanujachar R, Richards S, Hann I, Webb D
Adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL) constitute a distinct population from children and older adults. Based on patterns of referral, they may be treated by either paediatric or adult oncologists. As a group, AYA with ALL have a worse survival and...
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Postgrad Med. 2001 Apr;109(4):115-22; quiz 9
Authors: Ramahi TM
The ARBs are a new class of drugs with broad therapeutic potential in cardiovascular disease. These agents act by selectively inhibiting the AT1 subtype of the angiotensin II receptors. They are effective antihypertensive agents with promise, theoretically, in the prevention and regression of ventricular hypertrophy. They are...
from patients, caregivers and medical professionals dealing with this disease and many other diseases